NCT06700720View on ClinicalTrials.gov

YN001-004 in Patients With Coronary Atherosclerosis in Australia

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Coronary Artery DiseaseCoronary Atherosclerotic Disease
Interventions
DRUG

Dose 1 YN001

Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.

DRUG

Dose 2 YN001

Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.

DRUG

Evolocumab

Evolocumab 140 mg will be administered subcutaneously every 2 weeks.

Trial Locations (5)

1125

RECRUITING

Albury Wodonga Private Hospital, Albury

3025

RECRUITING

Altona Clinical Research, Melbourne

3199

RECRUITING

Peninsula Heart Centre, Melbourne

Unknown

NOT_YET_RECRUITING

Canberra Hospital, Canberra

RECRUITING

Core Research Group Pty Ltd, Milton

All Listed Sponsors
lead

Beijing Inno Medicine Co., Ltd.

INDUSTRY